Revenue by Product

(Billions of Yen)

  2015 2016 2017 2018 2019
  Sales 468.4 472.7 499.3 527.8 588.9
  Domestic - - 405.3 399.9 437.6
  Oncology 215.7 220.3 225.9 225.7 240.5
  Avastin® 93.8 92.1 93.1 95.6 95.6
  Perjeta® 10.6 11.9 13.6 16.1 30.7
  Herceptin® 32.7 34.1 33.6 28.1 26.7
  Alecensa® 8.0 11.9 16.7 20.6 23.0
  Tecentriq® - - - 9.1 20.6
  Rituxan® 29.0 32.1 33.4 21.3 11.9
  Kadcyla® 7.3 8.3 8.0 8.5 9.0
  Xeloda® 11.1 12.3 12.2 12.5 8.0
  Tarceva® 11.6 11.5 10.5 8.3 4.5
  Gazyva® - - - 0.6 3.6
  Alaglio® - - 0.0 0.3 0.3
  Rozlytrek® - - - - 0.0
  Bone and joint diseases 79.4 86.1 93.3 100.5 108.4
  Actemra® 26.8 30.2 33.1 38.2 41.8
  Edirol® 23.1 26.7 29.6 32.9 36.7
  Bonviva® 5.4 7.3 8.7 9.4 9.7
  Suvenyl® 10.5 9.3 8.8 7.8 7.2
  Renal diseases 45.4 41.1 39.3 36.3 34.6
  Mircera® 23.8 24.2 23.9 23.1 22.2
  Oxarol® 12.9 9.1 8.2 7.3 6.9
  Others 45.8 45.7 46.8 37.5 54.1
  Hemlibra® - - - 3.0 25.2
  CellCept® 7.0 7.9 8.9 9.0 9.3
  Tamiflu®(Ordinary use) 8.2 12.0 11.9 10.1 7.4
  Tamiflu®(Govt. stockpiles etc.) 0.0 1.5 5.0 0.5 3.2
  Foundation Medicine - - - - 0.4
  Overseas - - 94.0 127.9 151.3
  Actemra® 63.6 60.3 60.9 80.6 88.3
  To Roche 62.6 59.1 59.4 78.7 86.5
  Alecensa® 0.5 3.7 13.9 29.5 45.3
  To Roche 0.5 3.7 13.9 28.9 44.6
  Neutrogin® 14.8 12.2 12.3 11.1 9.9
  Hemlibra® - - 3.1 2.3 3.6
  To Roche - - 3.1 2.3 3.3
  Royalties and other operating income 30.4 19.1 34.9 51.9 97.3
  Royalty and profit-sharing income - - 17.2 24.1 76.5
  Other operating income - - 17.7 27.9 20.8
  Revenues 498.8 491.8 534.2 579.8 686.2
  Domestic 390.0 395.1 410.9 421.5 444.0
  Overseas 108.8 96.6 123.3 158.3 242.2

Sales by Strategic Field (FY2019)

  • Amounts are rounded to the nearest 0.1 billion yen.
    Variance and % are calculated based on amounts shown.
    Domestic sales are shown by each disease area.
  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top